Consensus ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.29 USD -3.79% Intraday chart for ProQR Therapeutics N.V. -4.59% +15.65%

Evolution of the average Target Price on ProQR Therapeutics N.V.

Price target over the last 5 years

History of analyst recommendation changes

7.gJ9bd_tFBJl3DeabSnX5XsFRiLUsCP59JITR_pOM8p0.-bIIIZMaaukRIIL8GgGjc7Eg8t11e4QHc_aXj6TAu67z3Cs8rCdy_xJltw~85cb97b48a62ff8d9bcdd60bd62d110a
Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating MT
Raymond James Adjusts ProQR Therapeutics' Price Target to $4 From $5, Keeps Outperform Rating MT
Chardan Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $2 MT
Citigroup Adjusts ProQR Therapeutics' Price Target to $1.80 From $2.10, Keeps Neutral Rating MT
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating MT
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating MT
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating MT
Raymond James Adjusts ProQR Therapeutics Price Target to $5 From $2, Maintains Outperform Rating MT
Cantor Fitzgerald Upgrades ProQR Therapeutics to Overweight From Neutral, Adjusts Price Target to $5 From $0.80 MT
HC Wainwright Adjusts Price Target on ProQR Therapeutics to $1.50 From $2, Reiterates Buy Rating MT
Cantor Fitzgerald Downgrades ProQR Therapeutics to Neutral From Overweight, Adjusts Price Target to $0.80 From $3.50 MT
Raymond James Upgrades ProQR Therapeutics to Outperform From Market Perform; Price Target is $2 MT
Chardan Research Downgrades ProQR Therapeutics to Neutral From Buy on Further Restructuring, Wind-Down of Inherited Retinal Disease Programs; $2 Price Target Removed MT
HC Wainwright Lowers ProQR Therapeutics N.V's Price Target to $2 From $4, Buy Rating Kept MT
Chardan Lowers Price Target for ProQR Therapeutics N.V to $2 From $2.50, Maintains Buy Rating MT
Chardan Capital Adjusts Price Target for ProQR Therapeutics N.V to $2.50 From $8, Maintains Buy Rating MT
JMP Securities Adjusts ProQR Therapeutics' Price Target to $5 from $8, Keeps Market Outperform Rating MT
Citigroup Adjusts ProQR Therapeutics' Price Target to $1 From $1.70, Maintains Neutral Rating MT
Chardan Adjusts Price Target on ProQR Therapeutics to $8 From $18, Maintains Buy Rating MT
Citigroup Downgrades ProQR Therapeutics to Neutral From Buy, Sets $1.70 Price Target MT
JMP Securities Adjusts ProQR Therapeutics' Price Target to $8 From $29, Maintains Market Outperform Rating MT
HC Wainwright Adjusts ProQR Therapeutics' Price Target to $4 From $20, Reiterates Buy Rating MT
Raymond James Downgrades ProQR Therapeutics to Market Perform From Strong Buy MT
Stifel Downgrades ProQR Therapeutics to Hold From Buy MT
Raymond James Starts ProQR Therapeutics at Strong Buy With $19 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.29 USD
Average target price
4.06 USD
Spread / Average Target
+77.30%
High Price Target
6 USD
Spread / Highest target
+162.02%
Low Price Target
1.8 USD
Spread / Lowest Target
-21.39%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ProQR Therapeutics N.V.

Chardan Research
Raymond James
Citigroup
Cantor Fitzgerald
HC Wainwright
JMP Securities
Stifel Nicolaus
Chardan
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings